Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National Medical Products Administration (NMPA) for its drug Rybelsus (semaglutide) for the treatment of type 2 diabetes. The approval covers filing numbers JXSS2200016, JXSS2200017, and JXSS2200018.
Rybelsus, recognized as the world’s first and currently only oral glucagon-like peptide-1 receptor agonist (GLP-1RA), is poised to establish a new benchmark for oral hypoglycemic drug treatment in China. Utilizing the SNAC absorption promoter technology, Rybelsus achieves a significant increase of approximately 100 times in molecular bioavailability when administered orally. The once-daily oral dosage effectively reduces blood sugar levels and maintains a stable blood drug concentration curve, offering a promising advancement in diabetes management.- Flcube.com
